You are here

Feb 27, 2014

Iproteos CEO, Teresa Tarrago, has been invited to participate and give a short talk in the Barcelona Institut d’Emprenedoria (BIE). The meeting will be held on 3rd March at the Historic Building of the Univeristy Barcelona. The meeting will deal with enterpreneurship successful cases.  

Feb 03, 2014

Iproteos has been selected to participate, among other 14 SME spanish companies, in the Commercialise Project, an innovative and pioneering coaching and mentoring program whose main purpose is to speed up and increase the commercialization of R&D&i projects.

Feb 03, 2014

  Iproteos is attending BioEurope Spring Meeting conference that will be held in Turin (Italy) at 10 -12 March 2014. The BioEurope Spring conference is an excellent opportunity to make networking and meet  with dealmakers from other biotech, pharma and finance companies. Further information can be found at:  

Sep 20, 2013

Iproteos is attending BioEurope Conference, that will be held in Viena (Austria) on 3th-4th of November 2013.

The annual BioEurope conference attracts leading dealmakers from biotech, pharma and finance, along with the most exciting emerging companies.

Further information can be found at:      

Sep 02, 2013

Iproteos' CEO, Teresa Tarrago, has been invited and interviewed at radio program named "Tot és possible" (Everything is possible) at RAC1. The interview covers topics such as the difficulties to find financing for a new biomedical company and the current status of the various research lines carried out by Iproteos.

More information can be found elsewhere:

Jul 30, 2013

Applications are invited for a fully-funded 3-year PhD Industrial position to be carried out at Iproteos S.L, a small biotech- pharma company located at Barcelona Science Park (Spain) in collaboration with Institute for Research on Biomedicine of Barcelona (IRB Barcelona).

The project aims to discover and synthesize new peptidic drugs to modulate the biological activity of proteins involved in the progress and the chronic progress of epilepsy through the combination of both computational and experimental methods.